METASTATIC MELANOMA

This study is testing a new type of targeted radiation drug called [212Pb]VMT01 for people with advanced melanoma that has returned or spread and has not responded to other treatments. The drug is designed to deliver a powerful dose of radiation directly to melanoma cells. Resear…

This early-phase study is testing a new type of cell therapy for people with advanced solid tumors, including melanoma, that have spread and are not responding to standard treatments. Doctors take a patient's own immune cells, modify them in a lab to better recognize and attack c…

This early-stage study is testing the safety of a new combination treatment for people with advanced melanoma that has continued to grow despite standard immunotherapy. The treatment involves infusing specially prepared 'memory-like' natural killer (NK) immune cells, either from …

This early-stage trial is testing the safety and initial effectiveness of a new oral drug, STC-15, when given alongside an existing immunotherapy called toripalimab. It will enroll about 188 adults with specific advanced cancers—including lung, melanoma, endometrial, and head/nec…

This study is testing a new combination treatment for people with metastatic melanoma that has spread to the liver. It combines a liver-targeted chemotherapy (HEPZATO KIT™) with a two-drug immunotherapy (Opdualag™). The main goals are to see if this combination is safe and if it …

This study is testing a personalized cell therapy called lifileucel for people with advanced melanoma that has worsened after standard immunotherapy. Doctors take immune cells from a patient's tumor, grow large numbers of them in a lab, and infuse them back into the patient to at…

This study is testing whether combining two existing cancer drugs—pembrolizumab and aldesleukin—works better than either alone for adults with advanced melanoma or kidney cancer that has stopped responding to standard treatments. The goal is to see if this combination can shrink …

This study is testing a new type of personalized cell therapy called OBX-115 in adults with advanced melanoma or non-small cell lung cancer that has progressed after standard treatments. Doctors take a patient's own immune cells from a tumor, genetically engineer them to be more …

This early-stage study is testing a personalized treatment called lifileucel for patients with advanced uveal melanoma (a rare eye cancer) or certain aggressive soft-tissue sarcomas. Doctors take a patient's own immune cells from their tumor, grow large numbers of them in a lab, …

This study is testing a new treatment approach for people who have had a kidney transplant and now have advanced skin cancer that cannot be removed by surgery or has spread. The goal is to see if a combination of cancer immunotherapy drugs (nivolumab and ipilimumab) can be given …

This study is testing whether adding focused, high-dose radiation to a small number of spots where melanoma is spreading can help patients stay on their current drug treatments longer. It involves adults with advanced melanoma whose cancer is mostly controlled by immunotherapy or…

This study aims to find the best radiation method for treating cancer that has spread to the brain. It compares giving one large radiation dose versus spreading the same total radiation over three smaller treatments. Researchers want to see which approach better controls the brai…

This study is testing whether combining two drugs, cabozantinib and nivolumab, can help control advanced melanoma or head and neck cancer that has worsened despite standard immunotherapy. It will enroll about 150 adults whose cancer has progressed on prior treatment. A key goal i…

This early-stage trial is testing a new combination treatment for melanoma that has spread to the brain. Researchers are giving patients immune cells from a universal donor (called NK cells) along with a standard chemotherapy drug (temozolomide). The study aims to find the safest…

This study is testing if freezing one growing tumor (cryoablation) while giving two immunotherapy drugs (ipilimumab and nivolumab) can help control advanced melanoma that has continued to grow despite prior immunotherapy. It aims to see if this combination is safe and effective f…

This study is testing if two oral drugs, binimetinib and encorafenib, can help control melanoma that has spread to the brain or spinal fluid. It is for adults whose melanoma has a specific genetic change called BRAF V600 and has progressed after prior treatment. The main goals ar…

This study is testing a new, modified drug called IOV-3001 in combination with a personalized cell therapy (lifileucel) for people with advanced melanoma that has spread or cannot be removed by surgery. The main goals are to find a safe dose and see how well the body handles the …

This study is testing a new method for giving the cancer drug atezolizumab. Researchers want to see if they can use lower doses, given less often, by carefully monitoring drug levels in a patient's blood. The goal is to see if this personalized approach can still control the canc…

This study is looking at how well immunotherapy drugs work for people in Slovenia with advanced melanoma that has spread. It will follow 100 adults receiving these drugs as their first treatment. Researchers also want to see if measuring a specific protein (PD-L1) in the tumor or…

This study is testing how well immunotherapy works as a first treatment for people in Slovenia with advanced melanoma that has spread. It will follow 40 patients to see how their cancer responds and how long it stays under control. Researchers will also collect blood, stool, and …

This trial is testing which of two drug combinations works better for people with advanced melanoma that has spread to the brain. One group gets three drugs (encorafenib, binimetinib, nivolumab), while the other gets two drugs (ipilimumab, nivolumab). The main goal is to see whic…

This study is testing an oral medication called avapritinib for people with advanced solid tumors that have spread and have specific genetic changes (mutations in the CKIT or PDGFRA genes). The drug aims to block the signals that help these tumor cells grow, potentially controlli…

This early-stage study is testing a modified virus called Adze1.C that's designed to infect and destroy cancer cells while potentially boosting the immune system. The virus is injected directly into tumors of adults with advanced melanoma that hasn't responded to standard treatme…

This study is testing a new, personalized vaccine designed to target the unique proteins on a patient's own cancer cells. It is being given alongside an existing immunotherapy drug (pembrolizumab) to see if the combination is safe and can help control advanced solid tumors that h…

This early-stage study is testing the safety and best dose of adding a drug called nilotinib to standard treatments for advanced melanoma that has a specific genetic change (BRAF V600) and has stopped responding to current targeted therapies. The goal is to see if this three-drug…

This study is testing a drug called mirdametinib for people with advanced melanoma that has a specific genetic change (NF1 mutation) and has continued to grow despite standard immunotherapy. The main goals are to see if the drug is safe and if it can help control the cancer. It's…

This study is testing if adding a freezing procedure (cryoablation) to standard radiation therapy works better to relieve pain from cancer that has spread to the bones. Researchers will compare the combination treatment to radiation alone in 40 patients with advanced cancers. The…

This study is monitoring patients for five years after they received an experimental cancer immunotherapy from Replimune. The goal is to check for any delayed side effects or safety issues that might appear long after treatment. About 50 patients with cancers like melanoma or liv…

This study aims to understand why some patients with advanced cancers like melanoma and lung cancer respond well to a common immunotherapy (anti-PD-1), while others do not. Researchers will collect blood samples from 500 patients to measure specific markers in immune cells during…